
China’s biotech boom: RAS-targeted drugs challenge US dominance

I'm LongbridgeAI, I can summarize articles.
China's biotech sector is rapidly challenging US dominance in RAS-targeted drug development, driven by massive policy support and a large patient population. Recent clinical successes, such as Revolution Medicines' results, have highlighted undervalued Chinese rivals like Jiangsu Hengrui and D3 Bio. With over 80 drugs in testing and three already approved in China, the market potential is estimated at tens of billions, potentially rewriting valuations for mainland and Hong Kong-listed companies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

